BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

565 related articles for article (PubMed ID: 23621866)

  • 1. Serum tryptase correlates with the KIT D816V mutation burden in adults with indolent systemic mastocytosis.
    Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB;
    Eur J Haematol; 2013 Aug; 91(2):106-11. PubMed ID: 23621866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis.
    Erben P; Schwaab J; Metzgeroth G; Horny HP; Jawhar M; Sotlar K; Fabarius A; Teichmann M; Schneider S; Ernst T; Müller MC; Giehl M; Marx A; Hartmann K; Hochhaus A; Hofmann WK; Cross NC; Reiter A
    Ann Hematol; 2014 Jan; 93(1):81-8. PubMed ID: 24281161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KIT D816V mutation burden does not correlate to clinical manifestations of indolent systemic mastocytosis.
    Broesby-Olsen S; Kristensen T; Vestergaard H; Brixen K; Møller MB; Bindslev-Jensen C;
    J Allergy Clin Immunol; 2013 Sep; 132(3):723-728. PubMed ID: 23587333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of sensitive KIT D816V detection on recognition of indolent Systemic Mastocytosis.
    De Matteis G; Zanotti R; Colarossi S; De Benedittis C; Garcia-Montero A; Bonifacio M; Sartori M; Aprili F; Caruso B; Paviati E; Carli G; Perbellini O; Zamò A; Bonadonna P; Pizzolo G; Guidi G; Martinelli G; Soverini S
    Leuk Res; 2015 Mar; 39(3):273-8. PubMed ID: 25582384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KIT D816V mutation-positive cell fractions in lesional skin biopsies from adults with systemic mastocytosis.
    Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB
    Dermatology; 2013; 226(3):233-7. PubMed ID: 23774045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V.
    Böhm A; Sonneck K; Gleixner KV; Schuch K; Pickl WF; Blatt K; Peter B; Herrmann H; Schernthaner GH; Pehamberger H; Rabitsch W; Sperr WR; Valent P
    Exp Hematol; 2010 Sep; 38(9):744-55. PubMed ID: 20553795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An immature immunophenotype of bone marrow mast cells predicts for multilineage D816V KIT mutation in systemic mastocytosis.
    Teodosio C; García-Montero AC; Jara-Acevedo M; Alvarez-Twose I; Sánchez-Muñoz L; Almeida J; Morgado JM; Matito A; Escribano L; Orfao A
    Leukemia; 2012 May; 26(5):951-8. PubMed ID: 22051531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating KIT D816V mutation-positive non-mast cells in peripheral blood are characteristic of indolent systemic mastocytosis.
    Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB;
    Eur J Haematol; 2012 Jul; 89(1):42-6. PubMed ID: 22469616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease.
    Hoermann G; Gleixner KV; Dinu GE; Kundi M; Greiner G; Wimazal F; Hadzijusufovic E; Mitterbauer G; Mannhalter C; Valent P; Sperr WR
    Allergy; 2014 Jun; 69(6):810-3. PubMed ID: 24750133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mastocytosis: state of the art.
    Horny HP; Sotlar K; Valent P
    Pathobiology; 2007; 74(2):121-32. PubMed ID: 17587883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective evaluation of the diagnostic value of sensitive KIT D816V mutation analysis of blood in adults with suspected systemic mastocytosis.
    Kristensen T; Vestergaard H; Bindslev-Jensen C; Mortz CG; Kjaer HF; Ollert M; Møller MB; Broesby-Olsen S;
    Allergy; 2017 Nov; 72(11):1737-1743. PubMed ID: 28432683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of the c-kit D816V mutation in systemic mastocytosis by allele-specific PCR.
    Schumacher JA; Elenitoba-Johnson KS; Lim MS
    J Clin Pathol; 2008 Jan; 61(1):109-14. PubMed ID: 17526803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitive KIT D816V mutation analysis of blood as a diagnostic test in mastocytosis.
    Kristensen T; Vestergaard H; Bindslev-Jensen C; Møller MB; Broesby-Olsen S;
    Am J Hematol; 2014 May; 89(5):493-8. PubMed ID: 24443360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM.
    Alvarez-Twose I; Zanotti R; González-de-Olano D; Bonadonna P; Vega A; Matito A; Sánchez-Muñoz L; Morgado JM; Perbellini O; García-Montero A; De Matteis G; Teodósio C; Rossini M; Jara-Acevedo M; Schena D; Mayado A; Zamò A; Mollejo M; Sánchez-López P; Cabañes N; Orfao A; Escribano L; ;
    J Allergy Clin Immunol; 2014 Feb; 133(2):520-8. PubMed ID: 23921094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F.
    Sotlar K; Bache A; Stellmacher F; Bültmann B; Valent P; Horny HP
    J Mol Diagn; 2008 Jan; 10(1):58-66. PubMed ID: 18165278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High frequency of concomitant mastocytosis in patients with acute myeloid leukemia exhibiting the transforming KIT mutation D816V.
    Fritsche-Polanz R; Fritz M; Huber A; Sotlar K; Sperr WR; Mannhalter C; Födinger M; Valent P
    Mol Oncol; 2010 Aug; 4(4):335-46. PubMed ID: 20471335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted ultradeep next-generation sequencing as a method for KIT D816V mutation analysis in mastocytosis.
    Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB;
    Eur J Haematol; 2016 Apr; 96(4):381-8. PubMed ID: 26095448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relocalization of KIT D816V to cell surface after dasatinib treatment: potential clinical implications.
    Bougherara H; Georgin-Lavialle S; Damaj G; Launay JM; Lhermitte L; Auclair C; Arock M; Dubreuil P; Hermine O; Poul MA
    Clin Lymphoma Myeloma Leuk; 2013 Feb; 13(1):62-9. PubMed ID: 23127495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Morphologically occult systemic mastocytosis in bone marrow: clinicopathologic features and an algorithmic approach to diagnosis.
    Reichard KK; Chen D; Pardanani A; McClure RF; Howard MT; Kurtin PJ; Wood AJ; Ketterling RP; King RL; He R; Morice WG; Hanson CA
    Am J Clin Pathol; 2015 Sep; 144(3):493-502. PubMed ID: 26276780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse Prognostic Impact of the
    Naumann N; Lübke J; Baumann S; Schwaab J; Hoffmann O; Kreil S; Dangelo V; Reiter L; Bugert P; Kristensen T; Sotlar K; Haselmann V; Schneider S; Metzgeroth G; Weiss C; Popp HD; Fabarius A; Hofmann WK; Cross NCP; Reiter A; Jawhar M
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33806359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.